Keyphrases
Confidence Interval
77%
Overall Survival
74%
Cluster Randomized Trial
58%
Weight Loss
50%
Odds Ratio
47%
Pancreatic Cancer
43%
Pancreaticoduodenectomy
43%
Breast Cancer Survivors
40%
Prostate Cancer Risk
37%
Health Studies
37%
Diet Study
37%
NIH-AARP
37%
Quality of Life
36%
Tumor
36%
Cancer Patients
35%
Randomized Trial
34%
Alzheimer's Disease
33%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
32%
Neoadjuvant
32%
Randomized Controlled Trial
31%
Generalized Estimating Equations
31%
Clinical Outcomes
31%
Behavioral Weight Loss
31%
Obesity
30%
Chemotherapy
29%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
29%
Pancreatic Ductal Adenocarcinoma
28%
Recurrence-free Survival
27%
Body Mass Index
27%
Enhanced Recovery
27%
Good Health
27%
High Risk
26%
Cetuximab
25%
Relative Efficiency
25%
Hazard Ratio
25%
After Surgery
24%
Phase II Trial
24%
Randomized Clinical Trial
23%
Multivariate Analysis
22%
Obese Women
22%
Symptom Experience
22%
Gynecologic Cancer Survivors
22%
Non-small Cell Lung Cancer (NSCLC)
22%
Pancreatic Neuroendocrine Tumors (pNETs)
22%
Decision Aid
22%
Diffuse Large B-cell Lymphoma (DLBCL)
22%
Computational Imaging
22%
Stereotactic Body Radiation Therapy
22%
Nab-paclitaxel
21%
Comorbidity
21%
Medicine and Dentistry
Neoplasm
100%
Malignant Neoplasm
80%
Overall Survival
76%
Surgery
63%
Breast Cancer
49%
Pancreaticoduodenectomy
47%
Odds Ratio
45%
Clinical Trial
39%
Pancreas Adenocarcinoma
39%
Health Care Cost
34%
Lung Cancer
32%
Neuroendocrine Tumor
32%
Obesity
32%
Computer Assisted Tomography
31%
Randomized Controlled Trial
31%
Diseases
31%
Body Mass Index
30%
Radiation Therapy
29%
Recurrent Disease
29%
Comorbidity
29%
Pancreas Cancer
29%
Nutrition
27%
Lung
27%
Quality of Life
26%
Progression Free Survival
25%
Arm
24%
Recurrence Free Survival
24%
Paclitaxel
23%
Head and Neck Squamous Cell Carcinoma
23%
Lung Transplantation
22%
Acute Myeloid Leukemia
22%
Uterine Cancer
22%
Prognostic Factor
21%
Multivariate Analysis
21%
Transplantation
20%
Gemcitabine
19%
Postoperative Complication
18%
Cetuximab
18%
Biological Marker
17%
Wart Virus
16%
Prevalence
16%
Colorectal Carcinoma
16%
Fibrosis
16%
Surgical Infection
16%
Cesarean Section
15%
Randomized Clinical Trial
15%
Oncology
15%
Cancer
15%
Hazard Ratio
15%
Oropharynx Carcinoma
14%